Trial Profile
Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 May 2019
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUME-Lung-1
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International; Boehringer Ingelheim Pharmaceuticals
- 16 Nov 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2017 Planned End Date changed from 20 Feb 2018 to 24 Oct 2017.
- 12 Jul 2017 Results of exploratory analysis (n=658) published in the Targeted Oncology